| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. | N Engl J Med | 2005 | 33.60 |
| 2 | Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. | J Clin Oncol | 2013 | 1.53 |
| 3 | Concordance between central and local laboratory HER2 testing from a community-based clinical study. | Clin Breast Cancer | 2006 | 1.33 |
| 4 | Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. | Breast Cancer Res Treat | 2008 | 1.32 |
| 5 | Development of the breast cancer education and risk assessment program. | Oncol Nurs Forum | 2003 | 0.76 |